Carlyle Bets Big On Late-Stage Biotech With Abingworth Buy
Partners Set Up Launch Tx
Tapping into Abingworth’s pioneering clinical co-development model, the private equity behemoth is using that experience to form Launch Therapeutics which will seek to partner with biotech and biopharma on "best‐in‐class, late‐stage clinical assets [and] bring life‐saving therapies to market better, faster and cheaper."
You may also be interested in...
Recent financings, including the $150m launch of Pathalys and a planned $100m IPO for Mineralys, illustrate the reality of biopharma funding in 2023 – that having near-term clinical trial milestones are key to fundraising this year. Companies with dwindling cash are conserving the funds they have left.
Public Company Edition: Third Harmonic hopes to double its money, raising up to $150m. Also, Halozyme priced a $625m note sale to retire debt and repurchase shares, while Viridian raised $270m in an offering after positive early data, and Clarus cut jobs while Endo finalized a restructuring plan.
AbbVie inks collaboration and option deal focused on targeted protein degradation with Plexium. Cend and Calabrius merge in an all-stock transaction.